Stocks tiptoed higher in relatively thin trading after the bell Tuesday, as mixed news emerged from various sectors.
was climbing 2.7% to $12.96, after the San Diego biotechnology company resubmitted its insomnia treatment, indiplon, for regulatory approval. Neurocrine says this is a complete response to the Food and Drug Administration's May 2006 approvable letter.
, based in Cambridge, Mass., said first-quarter continuing-operations income more than doubled to 7 cents a share, or $8.6 million (on a non-GAAP basis). That beats the average analyst estimate by a nickel a share. Revenue surged 39% to $121.3 million. Shares were adding 6%, or 36 cents, to $7.99.
Fellow tech name
underwent shaky trading, after it posted preliminary results for the quarter ended April 30. Sales came in at $97.3 million -- 5% lower than last year and
Wall Street targets. The Sunnyvale, Calif., optical-networking-parts maker also said results from a stock-option backdating review will necessitate a downward restatement that will likely be "material" for 2000 to 2007. Shares initially dropped postclose but recently reversed course to rise 1.6% at $3.72.
, an Akron, Ohio, purveyor of plastic resins, slid 10% to $21.50, after lowering its fiscal 2007 sales guidance to a range between $17 million and $23 million. Prior expectations had sales at $25 million to $30 million.